These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24699624)

  • 1. Redox modulation of adjacent thiols in VLA-4 by AS101 converts myeloid leukemia cells from a drug-resistant to drug-sensitive state.
    Layani-Bazar A; Skornick I; Berrebi A; Pauker MH; Noy E; Silberman A; Albeck M; Longo DL; Kalechman Y; Sredni B
    Cancer Res; 2014 Jun; 74(11):3092-103. PubMed ID: 24699624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia.
    Matsunaga T; Takemoto N; Sato T; Takimoto R; Tanaka I; Fujimi A; Akiyama T; Kuroda H; Kawano Y; Kobune M; Kato J; Hirayama Y; Sakamaki S; Kohda K; Miyake K; Niitsu Y
    Nat Med; 2003 Sep; 9(9):1158-65. PubMed ID: 12897778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitizing B- and T- cell Lymphoma Cells to Paclitaxel/Abraxane-Induced Death by AS101 via Inhibition of the VLA-4-IL10-Survivin Axis.
    Danoch H; Kalechman Y; Albeck M; Longo DL; Sredni B
    Mol Cancer Res; 2015 Mar; 13(3):411-22. PubMed ID: 25351768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tellurium compound AS101 ameliorates experimental autoimmune encephalomyelitis by VLA-4 inhibition and suppression of monocyte and T cell infiltration into the CNS.
    Lee JH; Halperin-Sheinfeld M; Baatar D; Mughal MR; Tae HJ; Kim JW; Carter A; Lustig A; Snir O; Lavie G; Okun E; Mattson MP; Sredni B; Taub DD
    Neuromolecular Med; 2014 Jun; 16(2):292-307. PubMed ID: 24272426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ammonium trichloro [1,2-ethanediolato-O,O']-tellurate cures experimental visceral leishmaniasis by redox modulation of Leishmania donovani trypanothione reductase and inhibiting host integrin linked PI3K/Akt pathway.
    Vishwakarma P; Parmar N; Chandrakar P; Sharma T; Kathuria M; Agnihotri PK; Siddiqi MI; Mitra K; Kar S
    Cell Mol Life Sci; 2018 Feb; 75(3):563-588. PubMed ID: 28900667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptotic death of hematopoietic tumor cells through potentiated and sustained adhesion to fibronectin via VLA-4.
    Saito Y; Owaki T; Matsunaga T; Saze M; Miura S; Maeda M; Eguchi M; Tanaka R; Taira J; Kodama H; Goto S; Niitsu Y; Terada H; Fukai F
    J Biol Chem; 2010 Mar; 285(10):7006-15. PubMed ID: 20007695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Small Tellurium Compound AS101 Ameliorates Rat Crescentic Glomerulonephritis: Association with Inhibition of Macrophage Caspase-1 Activity
    Hachmo Y; Kalechman Y; Skornick I; Gafter U; Caspi RR; Sredni B
    Front Immunol; 2017; 8():240. PubMed ID: 28326083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
    Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
    Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia.
    Matsunaga T; Fukai F; Miura S; Nakane Y; Owaki T; Kodama H; Tanaka M; Nagaya T; Takimoto R; Takayama T; Niitsu Y
    Leukemia; 2008 Feb; 22(2):353-60. PubMed ID: 17972943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tellurium-based immunomodulator, AS101 ameliorates adjuvant-induced arthritis in rats.
    Halpert G; Halperin Sheinfeld M; Monteran L; Sharif K; Volkov A; Nadler R; Schlesinger A; Barshak I; Kalechman Y; Blank M; Shoenfeld Y; Amital H
    Clin Exp Immunol; 2021 Mar; 203(3):375-384. PubMed ID: 33205391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model.
    Hayun M; Okun E; Hayun R; Gafter U; Albeck M; Longo DL; Sredni B
    Leukemia; 2007 Jul; 21(7):1504-13. PubMed ID: 17508000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts.
    Tazzari PL; Cappellini A; Ricci F; Evangelisti C; Papa V; Grafone T; Martinelli G; Conte R; Cocco L; McCubrey JA; Martelli AM
    Leukemia; 2007 Mar; 21(3):427-38. PubMed ID: 17215852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.
    Fialin C; Larrue C; Vergez F; Sarry JE; Bertoli S; Mansat-De Mas V; Demur C; Delabesse E; Payrastre B; Manenti S; Roche S; Récher C
    Leukemia; 2013 Feb; 27(2):325-35. PubMed ID: 22902361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.
    Allegretti M; Ricciardi MR; Licchetta R; Mirabilii S; Orecchioni S; Reggiani F; Talarico G; Foà R; Bertolini F; Amadori S; Torrisi MR; Tafuri A
    Sci Rep; 2015 Dec; 5():18137. PubMed ID: 26674543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia.
    Takam Kamga P; Bassi G; Cassaro A; Midolo M; Di Trapani M; Gatti A; Carusone R; Resci F; Perbellini O; Gottardi M; Bonifacio M; Nwabo Kamdje AH; Ambrosetti A; Krampera M
    Oncotarget; 2016 Apr; 7(16):21713-27. PubMed ID: 26967055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutral and positively charged thiols synergize the effect of the immunomodulator AS101 as a growth inhibitor of Jurkat cells, by increasing its uptake.
    Frei GM; Lebenthal I; Albeck M; Albeck A; Sredni B
    Biochem Pharmacol; 2007 Sep; 74(5):712-22. PubMed ID: 17632085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of AS101 on bryostatin 1-mediated differentiation induction, cell cycle arrest, and modulation of drug-induced apoptosis in human myeloid leukemia cells.
    Rao AS; Freemerman AJ; Jarvis WD; Chelliah J; Bear HD; Mikkelsen R; Grant S
    Leukemia; 1996 Jul; 10(7):1150-8. PubMed ID: 8683995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
    Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow stromal cells protect acute myeloid leukemia cells from anti-CD44 therapy partly through regulating PI3K/Akt-p27(Kip1) axis.
    Chen P; Huang H; Wu J; Lu R; Wu Y; Jiang X; Yuan Q; Chen Y
    Mol Carcinog; 2015 Dec; 54(12):1678-85. PubMed ID: 25408361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo.
    Lee C; Lin Y; Huang M; Lin C; Liu C; Chow J; Liu HE
    Leuk Lymphoma; 2006 Mar; 47(3):521-9. PubMed ID: 16396776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.